AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

It’s critical to understand what a digitally savvy HCP is in 2025 and what’s impeding pharma's communications with this ...

Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced Allergan Medical Institute (AMI) will open three new ...

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...

Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury: Carlsbad, California Thursday, February 13, 2025, 14:00 Hrs [IST] Lineage Cell Therapeutic ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

Here's a basket of top investments to consider for your TFSA in 2025 from low risk to high risk. The post Top Investments to ...

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...

AbbVie and Xilio Therapeutics have announced a collaboration to develop innovative tumor-activated immunotherapies, including masked T-cell engagers, utilizing Xilio’s proprietary technology ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Credit: Studio Romantic/Shutterstock. AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in conjunction with metronidazole for people ...